|
市場調查報告書
RNAi治療藥市場：2008年
RNAi Therapeutics 2008 Market Report
|
RNAi治療藥市場：2008年 是由出版商Select Biosciences, Ltd.在2007年11月所出版的。
這份英文市場調查報告書包含171 Pages 價格從美金3670起跳。
此報告書中調查分析了關於RNAi治療藥的疾病•治療領域、標的等級、運輸通道、開發動向（包括開發階段•企業•標的分子•治療領域等）、技術動向、智慧財產權等。另外還彙整了RNAi治療藥市場的市場機會與課題。報告書之內容摘要如下所示。
第1章 摘要
第2章 市場機會•課題
第3章 RNAi治療藥市場分析
- 調查應答者的地理分布
- 調查應答者的加盟團體
- 治療/疾病領域
- 最大課題：各治療/疾病領域
- 影響的時間線：各治療領域
- 運輸通道：各治療領域
- 標的藥劑等級
- 「Druggability」因素
- RNAi治療藥的主要課題
- RNAi治療藥市場的主要市場機會
第4章 開發中的RNAi治療藥
- 癌
- 心臟疾病
- 免疫疾病
- 傳染病
- 炎症
- 代謝疾病
- 神經疾病
- 眼疾
- 腎臟疾病
- 呼吸器官疾病
附錄I：調查手法
附錄II：於RNAi領域的技術動向
- 基因發現與抑制的檢測方法
- siRNA/shRNA圖書館
- 公開的大型哺乳類RNA圖書館
- TRC（The RNA Conosrtium）
- 標的檢驗比較
- 來自微型RNA的RNA干涉
- 微型RNA生物學機能
- 在癌治療中微型RNA所扮演的角色
- 各種技術的SWOT分析
附錄III：智慧財產權
附錄IV：企業概況
Abstract
This is the latest RNAi-based Therapeutics Market Report from Select
Biosciences. This report presents an up-to-date thorough analysis of the RNAi
therapeutics landscape based upon our continuing coverage of this dynamic
marketplace. This report presents an exhaustive analysis of all the
therapeutics areas where research efforts using RNAi-based therapeutics are
being focused: From Research/Pre-Clinical through Phase III Clinical Trials.
Select Biosciences proprietary market survey addresses druggability trends,
drug target classes (where RNAi therapeutics will impact) and different
therapeutic areas in terms of challenges/opportunities/quantitative industry
metrics-this highly valuable dataset is based on an extensive market analysis.
An extensive analysis of the Intellectual Property (IP) landscape in RNAi
therapeutics space, RNAi technology trends, and relevant company profiles make
this report a complete and timely industry analysis.
Topics Covered in this Report
- Opportunities and challenges in the RNAi therapeutics space
- Therapeutics areas impacted by RNAi therapeutics: Timeline for impact,
top-most challenge in each therapeutic area
- Different target classes and their amenability to targeting using RNAi
therapeutics
- Top-most drug target class for RNAi therapeutics
- Delivery approach by therapeutic area
- Factors that determine whether a given target will be druggable via
RNAi-based therapeutics
- Opportunities for vendors in the space
- Research/Pre-Clinical, Phase I, Phase II, and Phase III RNAi therapeutics
Clinical Trials: Details by company, molecular target, therapeutic/disease
area, partnership[s]
- Technology trends in the RNAi space
- Intellectual property (IP) in the RNAi therapeutics space: Landscape and
discussion of the various key patents
- Relevant company profiles: Partnerships, therapeutics/trials pipeline
Table of Contents
Chapter I. Executive Summary
Chapter II. Opportunities and Challenges In the Space
Chapter III. RNAi Therapeutics Market Analysis: Results of Market Survey performed by Select Biosciences to Analyze the Market Landscape
- Geographic Distribution of the Respondent Pool
- Affiliation of the Respondent Pool
- Challenges Impacting RNAi Therapeutics by Therapeutic/ Disease Area
- Top-Most Challenge by Therapeutic/ Disease Area
- Timeline of Impact by Therapeutic Area
- Delivery Approach by Therapeutic Area
- Drug Target Classes amenable to RNAi Therapeutics
- Druggability Factors
- Factors that determine whether a given drug target will be druggable via
RNAi-based therapeutics
- Key Challenges for RNAi-based therapeutics
- Opportunities in the RNAi-based Therapeutics marketplace -- [ie., what
products/ services would be of value to the industry]
Chapter IV. RNAi Therapeutics in Development
- Cancer
- Cardiac Disease
- Immunologic Disease
- Infectious Disease
- Inflammation
- Lifestyle
- Metabolic Disease
- Neurologic Disease
- Opthalmic Disease
- Renal Disease
- Respiratory Disease
Appendix I. Research Methodology
Appendix II. Technology Trends in the RNA Interference (RNAi) Space
- Scope
- End-user Segmentation
- Technologies for Inducing RNAi
- Methods for Detecting Gene Silencing
- Libraries of siRNAs/ shRNAs to Knock-down Genes en masse
- Publicly-Available Large-scale Mammalian RNAi Libraries
- The RNAi Consortium (TRC): A Cooperative Effort to
- Generate Large Libraries for Gene Knockdown
- Comparison of Strategies for Target Validation, Especially in the
Pharmaceutical Industry
- Market Shifts in the RNAi Space: Where is the Field Heading?
- MicroRNA-based RNAi Interference: The Leading-Edge of the RNAi Space
- Biological Function of microRNAs
- Role of MicroRNAs in Cancer
- MicroRNAs in Human Cancer: The Different Molecular Entities Identified and
the Conflicting Experimental Evidence Thus Far
- SWOT Analysis of the Various Technologies in the RNAi Space, and Vendors
Commercializing These Technologies
Appendix III. Intellectual Property [IP] in the RNAi Therapeutics Space
- Timeline
- Key Founding IP
- RNAi Patent Landscape and key claims in major patents
- RNAi Therapeutics IP Landscape-2D Maps of the Space, annotated with patent
filings for some of the key companies in the RNAi therapeutics space
Appendix IV. Relevant Company Profiles
- Alnylam Pharmaceuticals, Inc.
- Benitec Ltd.
- Calando Pharma
- Intradigm
- Nastech Pharmaceutical Company, Inc.
- Nucleonics, Inc.
- Opko Corporation
- Quark Biotech
- RXi Pharmaceuticals
- Santaris Pharma A/ S
- Silence Therapeutics AG
|
